The potential of epigenetic therapy to target the 3D epigenome in endocrine-resistant breast cancer
-
Published:2024-01-05
Issue:
Volume:
Page:
-
ISSN:1545-9993
-
Container-title:Nature Structural & Molecular Biology
-
language:en
-
Short-container-title:Nat Struct Mol Biol
Author:
Achinger-Kawecka JoannaORCID, Stirzaker ClareORCID, Portman Neil, Campbell ElyssaORCID, Chia Kee-Ming, Du QianORCID, Laven-Law Geraldine, Nair Shalima S., Yong Aliza, Wilkinson Ashleigh, Clifton Samuel, Milioli Heloisa H.ORCID, Alexandrou SarahORCID, Caldon C. ElizabethORCID, Song Jenny, Khoury Amanda, Meyer Braydon, Chen Wenhan, Pidsley Ruth, Qu Wenjia, Gee Julia M. W.ORCID, Schmitt Anthony, Wong Emily S.ORCID, Hickey Theresa E., Lim Elgene, Clark Susan J.ORCID
Abstract
AbstractThree-dimensional (3D) epigenome remodeling is an important mechanism of gene deregulation in cancer. However, its potential as a target to counteract therapy resistance remains largely unaddressed. Here, we show that epigenetic therapy with decitabine (5-Aza-mC) suppresses tumor growth in xenograft models of pre-clinical metastatic estrogen receptor positive (ER+) breast tumor. Decitabine-induced genome-wide DNA hypomethylation results in large-scale 3D epigenome deregulation, including de-compaction of higher-order chromatin structure and loss of boundary insulation of topologically associated domains. Significant DNA hypomethylation associates with ectopic activation of ER-enhancers, gain in ER binding, creation of new 3D enhancer–promoter interactions and concordant up-regulation of ER-mediated transcription pathways. Importantly, long-term withdrawal of epigenetic therapy partially restores methylation at ER-enhancer elements, resulting in a loss of ectopic 3D enhancer–promoter interactions and associated gene repression. Our study illustrates the potential of epigenetic therapy to target ER+ endocrine-resistant breast cancer by DNA methylation-dependent rewiring of 3D chromatin interactions, which are associated with the suppression of tumor growth.
Publisher
Springer Science and Business Media LLC
Subject
Molecular Biology,Structural Biology
Reference75 articles.
1. Farcas, A. M., Nagarajan, S., Cosulich, S. & Carroll, J. S. Genome-wide estrogen receptor activity in breast cancer. Endocrinology 162, bqaa224 (2021). 2. Garcia-Martinez, L., Zhang, Y., Nakata, Y., Chan, H. L. & Morey, L. Epigenetic mechanisms in breast cancer therapy and resistance. Nat. Commun. 12, 1786 (2021). 3. Ross-Innes, C. S. et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 481, 389–393 (2012). 4. Lupien, M. et al. Growth factor stimulation induces a distinct ERα cistrome underlying breast cancer endocrine resistance. Genes Dev. 24, 2219–2227 (2010). 5. Achinger-Kawecka, J. & Clark, S. J. Disruption of the 3D cancer genome blueprint. Epigenomics 9, 47–55 (2017).
|
|